NYSE · Healthcare
V2X, Inc. (VVX)
As-reported financials and recent SEC filings for V2X, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.48B
Net income
$77.9M
Net margin
1.7%
Diluted EPS
$2.45
ROE
7.2%
P/E (TTM)
25.9×
Market cap
$2.27B
Debt / equity
1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.48B | $4.32B | $3.96B | $2.89B | $1.78B |
| Gross profit | $373.4M | $343.0M | $334.9M | $295.0M | $160.4M |
| Operating income | $194.3M | $159.2M | $124.4M | $55.8M | $62.0M |
| Net income | $77.9M | $34.7M | $-22.6M | $-14.3M | $45.7M |
| Diluted EPS | $2.45 | $1.08 | $-0.73 | $-0.68 | $3.86 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-01
View on EDGAR →42026-05-15
View on EDGAR →SCHEDULE 13D/A2026-05-13
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →Go deeper on VVX
Search V2X, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.